Perioperative medicine & outcomes
Dexmedetomidine and acute kidney injury after non-cardiac surgery: A meta-analysis with trial sequential analysis
Pooled resultResult — go to the resultRelative risk 0.57 95% CI 0.40–0.83Authors' conclusion
Dexmedetomidine administration reduced the incidence of AKI and improved renal function after non-cardiac surgery.
Study context
- Population
- Adults undergoing non-cardiac surgery
- Participants
- 2,440 adults · 23 trials
- Comparison
- Perioperative dexmedetomidine vs normal saline
- Outcome
- Incidence of acute kidney injury (AKI) (KDIGO or AKIN criteria)
Methodological detailsrandom-effect model, trial sequential analysis, sensitivity analysis, GRADE level of evidence
- Random-effect model
- Trial sequential analysis
- Sensitivity analysis
- GRADE level of evidence
Pooled result
As reported in the abstract
Relative risk
0.57
95% CI 0.40–0.83
P = 0.003
By group
Dexmedetomidine vs Normal saline
RR 0.57 (95% CI 0.40–0.83); P = 0.003
Further pooled results
Renal function and inflammation parameters
- Dexmedetomidine decreased serum creatinine, blood urea nitrogen, cystatin C, TNF-α and interleukin-6, and increased urine output and eGFR
PONV and hospital LOS
- Dexmedetomidine reduced PONV and length of hospital stay
Safety
- Dexmedetomidine associated with increased bradycardia, but not hypotension
Original publication
Dexmedetomidine and acute kidney injury after non-cardiac surgery: A meta-analysis with trial sequential analysis. Anaesth Crit Care Pain Med. Published 21 February 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →